C
Cynthia X. Ma
Researcher at Washington University in St. Louis
Publications - 295
Citations - 11229
Cynthia X. Ma is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 235 publications receiving 8686 citations. Previous affiliations of Cynthia X. Ma include Eli Lilly and Company & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel,Molly J. DeCristo,April C. Watt,Haley BrinJones,Jaclyn Sceneay,Jaclyn Sceneay,Ben Li,Naveed Khan,Jessalyn M. Ubellacker,Jessalyn M. Ubellacker,Shaozhen Xie,Otto Metzger-Filho,Jeremy Hoog,Matthew J. Ellis,Cynthia X. Ma,Susanne Ramm,Ian E. Krop,Eric P. Winer,Thomas M. Roberts,Hye-Jung Kim,Sandra S. McAllister,Jean J. Zhao,Jean J. Zhao +22 more
TL;DR: It is shown that selective CDK4/6 inhibitors not only induce tumour cell cycle arrest, but also promote anti-tumour immunity, providing a rationale for new combination regimens comprising CDK 4/6 inhibitor and immunotherapies as anti-cancer treatment.
Journal ArticleDOI
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose,Shyam M. Kavuri,Adam C. Searleman,Wei Shen,Dong Shen,Daniel C. Koboldt,John Monsey,Nicholas Goel,Adam B. Aronson,Shunqiang Li,Cynthia X. Ma,Li Ding,Elaine R. Mardis,Matthew J. Ellis +13 more
TL;DR: It is shown that the majority of HER2 somatic mutations in breast cancer patients are activating mutations that likely drive tumorigenesis and the results suggest that patients with HER2 mutation–positive breast cancers could benefit from existing HER2-targeted drugs.
Journal ArticleDOI
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Shunqiang Li,Dong Shen,Jieya Shao,Robert J. Crowder,Wenbin Liu,Aleix Prat,Xiaping He,Shuying Liu,Jeremy Hoog,Charles Lu,Li Ding,Obi L. Griffith,Christopher A. Miller,Dave Larson,Robert S. Fulton,Michelle Harrison,Thomas B. Mooney,Joshua F. McMichael,Jingqin Luo,Yu Tao,Rodrigo Franco Gonçalves,Christopher E. Schlosberg,Jeffrey F. Hiken,Laila Saied,César Sánchez,Therese Giuntoli,Caroline Bumb,Crystal Cooper,R.T. Kitchens,Austin Lin,Chanpheng Phommaly,Sherri R. Davies,Jin Zhang,Megha Shyam Kavuri,Donna McEachern,Yiyu Dong,Cynthia X. Ma,Timothy J. Pluard,Michael Naughton,Ron Bose,Rama Suresh,Reida G. McDowell,Loren S. Michel,Rebecca Aft,William E. Gillanders,Katherine DeSchryver,Richard K. Wilson,Shaomeng Wang,Gordon B. Mills,Ana M. Gonzalez-Angulo,John R. Edwards,Christopher G. Maher,Charles M. Perou,Elaine R. Mardis,Matthew J. Ellis +54 more
TL;DR: Deep sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines.
Journal ArticleDOI
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey,Hope S. Rugo,P. Kelly Marcom,Erica L. Mayer,Francisco J. Esteva,Cynthia X. Ma,Minetta C. Liu,Anna Maria Storniolo,Mothaffar F. Rimawi,Andres Forero-Torres,Antonio C. Wolff,Timothy J. Hobday,Anastasia Ivanova,Wing Keung Chiu,Madlyn Ferraro,E. Burrows,Philip S. Bernard,Katherine A. Hoadley,Charles M. Perou,Eric P. Winer +19 more
TL;DR: Despite strong preclinical data, combination cetuximab plus carboplatin in metastatic TNBC produced responses in fewer than 20% of patients.
Journal ArticleDOI
Mechanisms of aromatase inhibitor resistance
TL;DR: The design and outcomes of clinical trials are considered with the perspective that resistance mechanisms are heterogeneous, and therefore biomarker and somatic mutation-based stratification and eligibility will be essential for improvements in patient outcomes.